Enlisting Monoclonal Antibodies in the Fight Against COVID-19
NIH Director's Blog: Drug Development
MAY 21, 2020
One advantage of this class of therapeutics is that the timelines for their development, testing, and approval are typically shorter than those for drugs made of chemical compounds, called small molecules. So, what exactly led up to this latest scientific achievement? In the U.S. medRxiv.
52 
Let's personalize your content